Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/first-in-class-investigational-sx-682-demonstrates-single-agent-efficacy-in-patients-with-hypomethylating-agent-failure-myelodysplastic-syndromes-301699265.html
https://www.prnewswire.com/news-releases/syntrix-completes-initial-sx-682-dosing-in-broad-phase-12-cancer-trial-campaign-now-encompassing-5-solid-cancer-types-plus-myelodysplastic-syndromes-301160630.html
https://www.prnewswire.com/news-releases/syntrix-discovers-desmetramadol-is-g-protein-biased-opioid-receptor-agonist-300998555.html
https://www.prnewswire.com/news-releases/syntrix-pharmaceuticals-to-present-positive-desmetramadol-trial-results-at-the-2019-pain-management-summit-300949283.html
https://www.prnewswire.com/news-releases/syntrix-pharmaceuticals-announces-publication-of-positive-double-blind-clinical-trials-showing-desmetramadol-has-the-analgesic-and-side-effect-profile-of-tramadol-without-its-metabolic-liabilities-300861610.html
https://www.prnewswire.com/news-releases/syntrix-wins-3-4m-nih-grant-to-conduct-phase-12-trial-of-sx-682-in-myelodysplastic-syndrome-300788624.html